Profile
Mr. Martin H.
Diggle is a Chairman at Vulpes Life Sciences Fund, a Director & Partner at Vulpes Investment Management Ltd. and a Portfolio Manager at Vulpes Ventures.
He is on the Board of Directors at Oxford BioDynamics Plc, Proteome Sciences Plc and Vulpes Investment Management Ltd. Mr. Diggle was previously employed as a Non-Executive Director by Scancell Holdings Plc, a Non-Independent Non-Executive Director by Oxford Biomedica Plc, a Director & Partner by Brunswick UBS, and a Non-Executive Director by Chronos Therapeutics Ltd. He also served on the board at Leucid Bio Ltd. He received his graduate degree from the University of Oxford.
Martin Diggle active positions
| Companies | Position | Start |
|---|---|---|
| PROTEOME SCIENCES PLC | Director/Board Member | 16/10/2014 |
| OXFORD BIODYNAMICS PLC | Director/Board Member | 15/04/2026 |
Vulpes Investment Management Ltd.
Vulpes Investment Management Ltd. Investment ManagersFinance Provides investment advice | Director/Board Member | 27/03/2015 |
Vulpes Investment Management Pte Ltd. (Venture Capital)
Vulpes Investment Management Pte Ltd. (Venture Capital) Investment ManagersFinance Vulpes Ventures invests in companies located in Southeast Asia, Australia and New Zealand. The firm focuses on a broad range of sectors and industries. It provides financing for seed and early stage capital requirements. | Private Equity Investor | - |
Vulpes Life Sciences Fund
Vulpes Life Sciences Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Chairman | - |
Former positions of Martin Diggle
| Companies | Position | End |
|---|---|---|
| OXFORD BIOMEDICA PLC | Director/Board Member | 03/02/2021 |
Brunswick UBS
Brunswick UBS Investment Banks/BrokersFinance Operates as a investment bank | Director/Board Member | 01/01/2003 |
Leucid Bio Ltd.
Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotech company that develops next generation CAR-T therapy | Director/Board Member | - |
| SCANCELL HOLDINGS PLC | Director/Board Member | - |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Education of Martin Diggle
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Proteome Sciences Plc
Proteome Sciences Plc Medical SpecialtiesHealth Technology Develops medical diagnostics used to identify specific diseases | Health Technology |
Oxford Biomedica Plc
Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
University of Oxford
University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Brunswick UBS
Brunswick UBS Investment Banks/BrokersFinance Operates as a investment bank | Finance |
Scancell Holdings Plc
Scancell Holdings Plc BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Health Technology |
Oxford BioDynamics Plc
Oxford BioDynamics Plc BiotechnologyHealth Technology Discovers and develops novel biomarkers | Health Technology |
Vulpes Investment Management Ltd.
Vulpes Investment Management Ltd. Investment ManagersFinance Provides investment advice | Finance |
Vulpes Life Sciences Fund
Vulpes Life Sciences Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Chronos Therapeutics Ltd.
Chronos Therapeutics Ltd. BiotechnologyHealth Technology Develops therapies in degenerative and behavioral brain diseases | Health Technology |
Vulpes Investment Management Pte Ltd. (Venture Capital)
Vulpes Investment Management Pte Ltd. (Venture Capital) Investment ManagersFinance Vulpes Ventures invests in companies located in Southeast Asia, Australia and New Zealand. The firm focuses on a broad range of sectors and industries. It provides financing for seed and early stage capital requirements. | Finance |
Leucid Bio Ltd.
Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotech company that develops next generation CAR-T therapy | Commercial Services |
- Stock Market
- Insiders
- Martin Diggle
















